ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

AstraZeneca, Pfizer and Astellas Pharma side by side

Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.

AstraZeneca×Pfizer×Astellas Pharma×Three at a time for now; Pro will compare up to ten.

At a glance

Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.

AstraZenecaPfizerAstellas Pharma
studies on the registry4,1974,073983
open to participants now29814738
phase 3 studies under way2009913
reach primary completion within a year1689214
programswith a study of their own in two years119+5 named only91+9 named only20

Pipeline by phase

Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.

Furthest phaseAstraZenecaPfizerAstellas Pharma
Phase 1

AstraZeneca: 25 of its 119 programs at phase 1

  1. AZD4954phase 1
  2. AZD1613phase 1
  3. AZD1390phase 1
  4. Actinium Ac 225-DOTA-Anti-STEAP2 Monoclonal Antibody AZD2284phase 1
  5. ALXN2230phase 1

and 20 more — sign in to see them all

21%

Pfizer: 42 of its 91 programs at phase 1

  1. polfurmetinibphase 1
  2. claturafenibphase 1
  3. PF-07985631phase 1
  4. PF-08642534phase 1
  5. Anti-integrin Beta-6 Antibody-drug Conjugate PF-08046876phase 1

and 37 more — sign in to see them all

46%

Astellas Pharma: 2 of its 20 programs at phase 1

  1. ASP2020phase 1
  2. Pan-KRAS Degrader ASP5834phase 1
10%
Phase 2

AstraZeneca: 47 of its 119 programs at phase 2

  1. AZD9550phase 2
  2. zadavotide guraxetanphase 2
  3. palacaparibphase 2
  4. Berzanoflastphase 2
  5. AZD7798phase 2

and 42 more — sign in to see them all

39%

Pfizer: 10 of its 91 programs at phase 2

  1. PF-07328948phase 2
  2. tegtociclibphase 2
  3. PF-08653945phase 2
  4. PF-08049820phase 2
  5. ompekimigphase 2

and 5 more — sign in to see them all

11%
45%
Phase 3

AstraZeneca: 28 of its 119 programs at phase 3

  1. rilvegostomigphase 3
  2. datopotamab deruxtecanphase 3
  3. tremelimumabphase 3
  4. volrustomigphase 3
  5. Autologous Bispecific BCMA/CD19-targeted CAR-T Cells GC012Fphase 3

and 23 more — sign in to see them all

24%

Pfizer: 31 of its 91 programs at phase 3

  1. berobenatidephase 3
  2. tivunatamigphase 3
  3. tilrekimigphase 3
  4. ritlecitinibphase 3
  5. abrysvophase 3

and 26 more — sign in to see them all

34%

Astellas Pharma: 4 of its 20 programs at phase 3

  1. fezolinetantphase 3
  2. setidegrasibphase 3
  3. emaretamigphase 3
  4. gilteritinibphase 3
20%
Approved, new studies

AstraZeneca: 19 of its 119 programs at approved, new studies

  1. durvalumabapproved, new study
  2. acalabrutinibapproved, new study
  3. trastuzumab deruxtecanapproved, new study
  4. osimertinibapproved, new study
  5. anifrolumabapproved, new study

and 14 more — sign in to see them all

16%

Pfizer: 8 of its 91 programs at approved, new studies

  1. rimegepantapproved, new study
  2. tucatinibapproved, new study
  3. elranatamabapproved, new study
  4. tisotumab vedotinapproved, new study
  5. diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccineapproved, new study

and 3 more — sign in to see them all

9%

Astellas Pharma: 5 of its 20 programs at approved, new studies

  1. zolbetuximabapproved, new study
  2. enfortumab vedotinapproved, new study
  3. enzalutamideapproved, new study
  4. avacincaptad pegolapproved, new study
  5. Sirolimusapproved, new study
25%

Readouts ahead

Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.

Nov ’26DecJan ’27FebMarAprMayJunJulAugSepOct
AstraZeneca60 readouts · 16 phase 3

AstraZeneca, Nov ’26: 4 programs whose next study reaches primary completion

  1. Autologous dnTGF-BRII-armored Anti-STEAP2 CAR T-cells AZD0754phase 2 · Nov 24 · NCT06267729
  2. STEAP2-targeting Radioconjugate AZD2287phase 2 · Nov 24 · NCT06267729
  3. durvalumabapproved, new study · Nov 30 · NCT07081633
  4. tremelimumabphase 3 · Nov 30 · NCT07081633

AstraZeneca, Dec ’26: 7 programs whose next study reaches primary completion, 2 in phase 3

  1. eculizumabapproved, new study · Dec 7 · NCT06724809
  2. AZD3974phase 1 · Dec 8 · NCT07290283
  3. baxdrostatphase 3 · Dec 10 · NCT07222917
  4. dapagliflozinapproved, new study · Dec 10 · NCT07222917
  5. benralizumabapproved, new study · Dec 23 · NCT05692180

and 2 more — sign in to see them all

AstraZeneca, Jan ’27: 13 programs whose next study reaches primary completion, 6 in phase 3

  1. laroprovstatphase 3 · Jan 4 · NCT07000136
  2. anifrolumabapproved, new study · Jan 6 · NCT05925803
  3. monalizumabphase 3 · Jan 8 · NCT05221840
  4. oleclumabphase 3 · Jan 8 · NCT05221840
  5. datopotamab deruxtecanphase 3 · Jan 11 · NCT06417814

and 8 more — sign in to see them all

AstraZeneca, Feb ’27: 7 programs whose next study reaches primary completion, 3 in phase 3

  1. Autologous Bispecific BCMA/CD19-targeted CAR-T Cells GC012Fphase 3 · Feb 1 · NCT06530849
  2. trastuzumab deruxtecanapproved, new study · Feb 10 · NCT06271837
  3. Berzanoflastphase 2 · Feb 11 · NCT07215702
  4. acalabrutinibapproved, new study · Feb 15 · NCT02972840
  5. zibotentanphase 3 · Feb 18 · NCT06087835

and 2 more — sign in to see them all

AstraZeneca, Mar ’27: 4 programs whose next study reaches primary completion

  1. AZD7760phase 2 · Mar 8 · NCT06749457
  2. AZD4954phase 1 · Mar 17 · NCT07812077
  3. AZD0543phase 1 · Mar 24 · NCT07824622
  4. Anti-Claudin 18.2 Antibody-drug Conjugate AZD4360phase 2 · Mar 31 · NCT06921928

AstraZeneca, Apr ’27: 3 programs whose next study reaches primary completion, 1 in phase 3

  1. AZD1043phase 1 · Apr 9 · NCT07511205
  2. camizestrantphase 3 · Apr 20 · NCT05774951
  3. ombetoxabartphase 2 · Apr 20 · NCT07285213

AstraZeneca, May ’27: 5 programs whose next study reaches primary completion, 2 in phase 3

  1. rilvegostomigphase 3 · May 4 · NCT04379596
  2. Anti-CD20/Anti-CD3/Anti-CD8 Trispecific Antibody AZD5492phase 2 · May 5 · NCT06916806
  3. AZD1613phase 1 · May 22 · NCT07228364
  4. Budesonideapproved, new study · May 31 · NCT07073950
  5. formoterolapproved, new study · May 31 · NCT07073950

AstraZeneca, Jun ’27: 3 programs whose next study reaches primary completion, 1 in phase 3

  1. tozorakimabphase 3 · Jun 7 · NCT06932263
  2. ravulizumabapproved, new study · Jun 25 · NCT07308574
  3. Anti-GPC3 T Cell-engaging Antibody AZD9793phase 2 · Jun 30 · NCT06795022

AstraZeneca, Jul ’27: 3 programs whose next study reaches primary completion

  1. ALXN1920phase 2 · Jul 2 · NCT07157787
  2. AZD2389phase 2 · Jul 7 · NCT07610837
  3. SC rilvegostomig + rHuphase 1 · Jul 19 · NCT07161414

AstraZeneca, Aug ’27: 4 programs whose next study reaches primary completion

  1. ALXN2230phase 1 · Aug 9 · NCT07352423
  2. AZD0240phase 1 · Aug 30 · NCT06218914
  3. SC durvalumab + rHuphase 1 · Aug 30 · NCT07391670
  4. AZD6793phase 2 · Aug 31 · NCT07082738

AstraZeneca, Sep ’27: 2 programs whose next study reaches primary completion

  1. palacaparibphase 2 · Sep 29 · NCT05123482
  2. puxitatug samrotecanphase 3 · Sep 29 · NCT05123482

AstraZeneca, Oct ’27: 5 programs whose next study reaches primary completion, 1 in phase 3

  1. opemalirsenphase 2 · Oct 4 · NCT06824987
  2. cevolisiranphase 2 · Oct 11 · NCT06744647
  3. tarperprumigphase 2 · Oct 11 · NCT07160608
  4. torvutatug samrotecanphase 3 · Oct 15 · NCT07402915
  5. sodium zirconium cyclosilicateapproved, new study · Oct 30 · NCT07944378
Pfizer37 readouts · 10 phase 3

Pfizer, Nov ’26: 1 program whose next study reaches primary completion, 1 in phase 3

  1. rimegepantapproved, new study · Nov 29 · NCT06641466

Pfizer, Dec ’26: 8 programs whose next study reaches primary completion, 2 in phase 3

  1. ritlecitinibphase 3 · Dec 2 · NCT07029711
  2. vepdegestrantphase 3 · Dec 4 · NCT07231991
  3. VLA15phase 3 · Dec 4 · NCT07500506
  4. prifetrastatphase 3 · Dec 8 · NCT07721402
  5. disitamab vedotinphase 3 · Dec 11 · NCT04879329

and 3 more — sign in to see them all

Pfizer, Jan ’27: 3 programs whose next study reaches primary completion, 1 in phase 3

  1. PF-08653945phase 2 · Jan 13 · NCT07725809
  2. abrysvophase 3 · Jan 18 · NCT05035212
  3. berobenatidephase 3 · Jan 27 · NCT07508241

Pfizer, Feb ’27: 5 programs whose next study reaches primary completion, 1 in phase 3

  1. osivelotorphase 3 · Feb 8 · NCT06507904
  2. tilrekimigphase 3 · Feb 20 · NCT07792941
  3. PF-07328948phase 2 · Feb 23 · NCT07269301
  4. atirmociclibphase 3 · Feb 26 · NCT05262400
  5. mevrometostatphase 3 · Feb 28 · NCT06551324

Pfizer, Mar ’27: 3 programs whose next study reaches primary completion

  1. PG4phase 3 · Mar 4 · NCT06524414
  2. PF-08161842phase 1 · Mar 17 · NCT07897708
  3. PF-08103402phase 1 · Mar 30 · NCT07660731

Pfizer, Apr ’27: 2 programs whose next study reaches primary completion, 1 in phase 3

  1. PF-08642534phase 1 · Apr 21 · NCT07731139
  2. PG4 Multivalent Vaccinephase 3 · Apr 26 · NCT07794748

Pfizer, May ’27: 2 programs whose next study reaches primary completion, 1 in phase 3

  1. abrocitinibphase 3 · May 2 · NCT06807268
  2. marstacimabphase 3 · May 5 · NCT06703606

Pfizer, Jun ’27: 3 programs whose next study reaches primary completion

  1. PF-07832837phase 1 · Jun 2 · NCT06564389
  2. Pneumococcal 20-Valent Conjugate Vaccinephase 3 · Jun 10 · NCT07023081
  3. sigvotatug vedotinphase 3 · Jun 16 · NCT04389632
·

Pfizer, Aug ’27: 4 programs whose next study reaches primary completion, 1 in phase 3

  1. elranatamabapproved, new study · Aug 4 · NCT05317416
  2. zavegepantphase 3 · Aug 12 · NCT06995729
  3. claturafenibphase 1 · Aug 31 · NCT05355701
  4. polfurmetinibphase 1 · Aug 31 · NCT05538130

Pfizer, Sep ’27: 3 programs whose next study reaches primary completion, 2 in phase 3

  1. PF-08065010phase 1 · Sep 1 · NCT07235163
  2. ibuzatrelvirphase 3 · Sep 28 · NCT07013474
  3. remdesivirphase 3 · Sep 28 · NCT07013474

Pfizer, Oct ’27: 3 programs whose next study reaches primary completion

  1. tivunatamigphase 3 · Oct 18 · NCT07227012
  2. PA-001phase 1 · Oct 21 · NCT07086677
  3. PG4 in Buffer 1 with low dose PA-002phase 1 · Oct 21 · NCT07086677
Astellas Pharma9 readouts · 2 phase 3·

Astellas Pharma, Dec ’26: 3 programs whose next study reaches primary completion, 1 in phase 3

  1. Anti-Claudin 18.2 Antibody-drug Conjugate ASP546Cphase 2 · Dec 30 · NCT06792435
  2. enfortumab vedotinapproved, new study · Dec 31 · NCT06862219
  3. zolbetuximabapproved, new study · Dec 31 · NCT06396091
···

Astellas Pharma, Apr ’27: 2 programs whose next study reaches primary completion

  1. enzalutamideapproved, new study · Apr 30 · NCT07783282
  2. fezolinetantphase 3 · Apr 30 · NCT07783282
·

Astellas Pharma, Jun ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. avacincaptad pegolapproved, new study · Jun 30 · NCT06970665
···

Astellas Pharma, Oct ’27: 3 programs whose next study reaches primary completion

  1. Methylprednisolonephase 2 · Oct 31 · NCT07052929
  2. Prednisolonephase 2 · Oct 31 · NCT07052929
  3. Sirolimusapproved, new study · Oct 31 · NCT07052929
size: programs that monthincludes phase 3Dates are estimates the sponsors file and often move.

Changed in the last 90 days

Since Aug 23, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.

AstraZeneca

New programs 2

Reached a new phase 1

Study stopped 0

None

Primary completion later 23

Pfizer

New programs 6

Reached a new phase 0

None

Study stopped 3

  • PF-07868489phase 2 · terminated Nov 2 · none of its studies left running“The study terminated due to a business decision and was not based on any safety and/or efficacy concerns.” · NCT07073820
  • vepdegestrantphase 2 · terminated Oct 27“Enrollment was permanently closed for strategic business reasons after 20 participants enrolled in Ph 1b. T…” · NCT05573555
  • vepdegestrantphase 2 · terminated Oct 27“Enrollment was permanently closed for strategic business reasons after 11 participants enrolled in Ph1b. Th…” · NCT06125522

Primary completion later 7

Astellas Pharma

New programs 1

  • ASP2957phase 2 · first study · Oct 9 · Myopathies, Structural, Congenital

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 1

Where they overlap

Conditions where at least two of them have programs: 48 in all, the first 12 here. A program counts in each condition its studies name most.

ConditionAstraZenecaPfizerAstellas Pharma
Carcinoma, Non-Small-Cell Lungall three · compare here

AstraZeneca in Carcinoma, Non-Small-Cell Lung: 16 programs

  1. rilvegostomigphase 3
  2. datopotamab deruxtecanphase 3
  3. tremelimumabphase 3
  4. volrustomigphase 3
  5. ceralasertibphase 3

and 11 more — sign in to see them all

Their studies: AstraZeneca’s studies of Carcinoma, Non-Small-Cell Lung in search

Pfizer in Carcinoma, Non-Small-Cell Lung: 8 programs

  1. tivunatamigphase 3
  2. prifetrastatphase 3
  3. disitamab vedotinphase 3
  4. sigvotatug vedotinphase 3
  5. ponsegromabphase 3

and 3 more — sign in to see them all

Their studies: Pfizer’s studies of Carcinoma, Non-Small-Cell Lung in search

Astellas Pharma in Carcinoma, Non-Small-Cell Lung: 3 programs

  1. setidegrasibphase 3
  2. gilteritinibphase 3
  3. Pan-KRAS Degrader ASP5834phase 1

Their studies: Astellas Pharma’s studies of Carcinoma, Non-Small-Cell Lung in search

Breast Neoplasmsall three · compare here

AstraZeneca in Breast Neoplasms: 10 programs

  1. datopotamab deruxtecanphase 3
  2. saruparibphase 3
  3. capivasertibphase 3
  4. camizestrantphase 3
  5. puxitatug samrotecanphase 3

and 5 more — sign in to see them all

Their studies: AstraZeneca’s studies of Breast Neoplasms in search

Pfizer in Breast Neoplasms: 7 programs

  1. atirmociclibphase 3
  2. vepdegestrantphase 3
  3. prifetrastatphase 3
  4. disitamab vedotinphase 3
  5. tegtociclibphase 2

and 2 more — sign in to see them all

Their studies: Pfizer’s studies of Breast Neoplasms in search

Astellas Pharma in Breast Neoplasms: 2 programs

  1. enzalutamideapproved, new study
  2. Sirolimusapproved, new study

Their studies: Astellas Pharma’s studies of Breast Neoplasms in search

Prostatic Neoplasmsall three · compare here

AstraZeneca in Prostatic Neoplasms: 13 programs

  1. saruparibphase 3
  2. capivasertibphase 3
  3. zibotentanphase 3
  4. Actinium-225phase 3
  5. zadavotide guraxetanphase 2

and 8 more — sign in to see them all

Their studies: AstraZeneca’s studies of Prostatic Neoplasms in search

Pfizer in Prostatic Neoplasms: 1 program

  1. mevrometostatphase 3

Their studies: Pfizer’s studies of Prostatic Neoplasms in search

Astellas Pharma in Prostatic Neoplasms: 4 programs

  1. fezolinetantphase 3
  2. Prednisolonephase 2
  3. ASP5541phase 2
  4. enzalutamideapproved, new study

Their studies: Astellas Pharma’s studies of Prostatic Neoplasms in search

Asthmaall three · compare here

AstraZeneca in Asthma: 10 programs

  1. tozorakimabphase 3
  2. BFF MDIphase 3
  3. GP MDIphase 3
  4. londamocitinibphase 2
  5. sunakimentphase 2

and 5 more — sign in to see them all

Their studies: AstraZeneca’s studies of Asthma in search

Pfizer in Asthma: 3 programs

  1. tilrekimigphase 3
  2. zavegepantphase 3
  3. PF-08103402phase 1

Their studies: Pfizer’s studies of Asthma in search

Astellas Pharma in Asthma: 1 program

  1. Prednisolonephase 2

Their studies: Astellas Pharma’s studies of Asthma in search

Renal Insufficiencyall three · compare here

AstraZeneca in Renal Insufficiency: 8 programs

  1. elecoglipronphase 3
  2. lenbelintidephase 3
  3. zibotentanphase 3
  4. balcinrenonephase 3
  5. opemalirsenphase 2

and 3 more — sign in to see them all

Their studies: AstraZeneca’s studies of Renal Insufficiency in search

Pfizer in Renal Insufficiency: 4 programs

  1. prifetrastatphase 3
  2. abrocitinibphase 3
  3. osivelotorphase 3
  4. PF-07328948phase 2

Their studies: Pfizer’s studies of Renal Insufficiency in search

Astellas Pharma in Renal Insufficiency: 2 programs

  1. fezolinetantphase 3
  2. Sirolimusapproved, new study

Their studies: Astellas Pharma’s studies of Renal Insufficiency in search

Neoplasmsall three · compare here

AstraZeneca in Neoplasms: 6 programs

  1. saruparibphase 3
  2. ceralasertibphase 3
  3. Leucovorinphase 2
  4. Ramucirumabphase 2
  5. AZD1390phase 1

and 1 more — sign in to see them all

Their studies: AstraZeneca’s studies of Neoplasms in search

Pfizer in Neoplasms: 2 programs

  1. polfurmetinibphase 1
  2. tucatinibapproved, new study

Their studies: Pfizer’s studies of Neoplasms in search

Astellas Pharma in Neoplasms: 3 programs

  1. setidegrasibphase 3
  2. enfortumab vedotinapproved, new study
  3. enzalutamideapproved, new study

Their studies: Astellas Pharma’s studies of Neoplasms in search

Pulmonary Disease, Chronic Obstructiveall three · compare here

AstraZeneca in Pulmonary Disease, Chronic Obstructive: 8 programs

  1. tozorakimabphase 3
  2. GP MDIphase 3
  3. AZD6793phase 2
  4. Treatment A: BGF MDI HFOphase 1
  5. tezepelumabapproved, new study

and 3 more — sign in to see them all

Their studies: AstraZeneca’s studies of Pulmonary Disease, Chronic Obstructive in search

Pfizer in Pulmonary Disease, Chronic Obstructive: 1 program

  1. tilrekimigphase 3

Their studies: Pfizer’s studies of Pulmonary Disease, Chronic Obstructive in search

Astellas Pharma in Pulmonary Disease, Chronic Obstructive: 1 program

  1. Prednisolonephase 2

Their studies: Astellas Pharma’s studies of Pulmonary Disease, Chronic Obstructive in search

Stomach Neoplasmsall three · compare here

Pfizer in Stomach Neoplasms: 1 program

  1. disitamab vedotinphase 3

Their studies: Pfizer’s studies of Stomach Neoplasms in search

Astellas Pharma in Stomach Neoplasms: 1 program

  1. zolbetuximabapproved, new study

Their studies: Astellas Pharma’s studies of Stomach Neoplasms in search

Multiple Myelomaall three · compare here

Pfizer in Multiple Myeloma: 1 program

  1. elranatamabapproved, new study

Their studies: Pfizer’s studies of Multiple Myeloma in search

Astellas Pharma in Multiple Myeloma: 1 program

  1. Methylprednisolonephase 2

Their studies: Astellas Pharma’s studies of Multiple Myeloma in search

Neoplasm Metastasisall three · compare here

AstraZeneca in Neoplasm Metastasis: 3 programs

  1. saruparibphase 3
  2. camizestrantphase 3
  3. trastuzumab deruxtecanapproved, new study

Their studies: AstraZeneca’s studies of Neoplasm Metastasis in search

Pfizer in Neoplasm Metastasis: 1 program

  1. tisotumab vedotinapproved, new study

Their studies: Pfizer’s studies of Neoplasm Metastasis in search

Astellas Pharma in Neoplasm Metastasis: 1 program

  1. enzalutamideapproved, new study

Their studies: Astellas Pharma’s studies of Neoplasm Metastasis in search

Arthritis, Rheumatoidall three · compare here

AstraZeneca in Arthritis, Rheumatoid: 2 programs

  1. surovatamigphase 3
  2. AZD1163phase 2

Their studies: AstraZeneca’s studies of Arthritis, Rheumatoid in search

Pfizer in Arthritis, Rheumatoid: 1 program

  1. ritlecitinibphase 3

Their studies: Pfizer’s studies of Arthritis, Rheumatoid in search

Astellas Pharma in Arthritis, Rheumatoid: 1 program

  1. Prednisolonephase 2

Their studies: Astellas Pharma’s studies of Arthritis, Rheumatoid in search

Obesity2 of 3 · compare here

AstraZeneca in Obesity: 4 programs

  1. elecoglipronphase 3
  2. lenbelintidephase 3
  3. AZD9550phase 2
  4. AZD1043phase 1

Their studies: AstraZeneca’s studies of Obesity in search

Pfizer in Obesity: 7 programs

  1. berobenatidephase 3
  2. PF-08653945phase 2
  3. danuglipronphase 2
  4. PF-07976016phase 2
  5. MET233phase 2

and 2 more — sign in to see them all

Their studies: Pfizer’s studies of Obesity in search

–

Show all 48

Same targetBetaPro · free during the beta

Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.

TargetAstraZenecaPfizerAstellas Pharma
CD3Esurovatamig, Anti-CD20/Anti-CD3/Anti-CD8 Trispecific Antibody AZD5492, Anti-Claudin18.2/Anti-CD3 Bispecific Antibody AZD5863, Anti-GPC3 T Cell-engaging Antibody AZD9793, Anti-STEAP2/Anti-CD3/Anti-CD8 Trispecific Antibody AZD6621elranatamabruleemaretamigrule
KRASPan-KRAS Inhibitor JAB-23E73, AZD0240Pan-KRAS Inhibitor PF-07985045rulePan-KRAS Degrader ASP5834rule
CLDN18sonesitatug vedotin, Anti-Claudin18.2/Anti-CD3 Bispecific Antibody AZD5863, Anti-Claudin 18.2 Antibody-drug Conjugate AZD4360rule–zolbetuximabrule, emaretamigrule, Anti-Claudin 18.2 Antibody-drug Conjugate ASP546Crule
GLP1RAZD9550berobenatide, PF-08642534, PF-08656795, danuglipronrule–
PDCD1rilvegostomig, volrustomigsasanlimab, tivunatamig–
BTKacalabrutinibrule, pirtobrutinibruleritlecitinibrule–
CD274durvalumabrulefetrastobart vedotin, PD-L1-directed TLR7 Agonist PF-08046037rule–
ERBB2trastuzumab deruxtecanruledisitamab vedotin, tucatinibrule–
NR3C1Budesoniderule–Methylprednisolonerule, Prednisolonerule
TNFRSF17Autologous Bispecific BCMA/CD19-targeted CAR-T Cells GC012F, Allogeneic Anti-BCMA CAR T-cells AZD4045elranatamabrule–
ARAndrogen Receptor Degrader AZD9750rule–enzalutamiderule
CDK4atirmociclibatirmociclib–
ESR1camizestrantrulevepdegestrantrule–
TACSTD2datopotamab deruxtecanrule–Anti-TROP2/Topoisomerase I Inhibitor-STING Agonist Immunostimulatory ADC ASP2998rule
TFPIandexanet alfarulemarstacimabrule–
TSLPtezepelumabruletilrekimig–
TTRacoramidisruletafamidisrule–
A target, or a pathogen for a vaccine, known for: AstraZeneca 68 of 119 · Pfizer 67 of 91 · Astellas Pharma 12 of 20 programs (57 of them by rule). Most early programs are named only by a code and their companies do not say what they act on, so this list is short and grows as targets are read.

What this can't show

  • Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
  • Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
  • Readout dates are the sponsors’ estimates, not results.
  • A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
  • “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.
  • Programs a company names but has not registered are counted apart (AstraZeneca: 5, Pfizer: 9).